Daniel Simard
2 Papers
1 Citations
Daniel Simard is an academic researcher. The author has contributed to research in topics: KRAS & Cancer. The author has an hindex of 1, co-authored 2 publications.
Chat about Author
Papers
Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers
Malvika Koundinya,Judith Sudhalter,Albane Courjaud,Bruno Lionne,Gaetan Touyer,Luc Bonnet,Isabelle Menguy,Isabelle Schreiber,Christelle Perrault,Stephanie Vougier,Brigitte Benhamou,Bailin Zhang,Timothy He,Qiang Gao,Patricia Gee,Daniel Simard,M. Paola Castaldi,Ronald Tomlinson,Stephan Reiling,Matthieu Barrague,Richard Newcombe,Hui Cao,Yanjun Wang,Fangxian Sun,Joshua Murtie,Mark Munson,Eric Yang,David Harper,Monsif Bouaboula,Jack Pollard,Claudine Grepin,Carlos Garcia-Echeverria,Hong Cheng,Francisco Adrian,Christopher Winter,Stuart Licht,Ivan Cornella-Taracido,Rosalia Arrebola,Aaron J. Morris +38 more
TL;DR: A high-throughput synthetic lethal screen for small molecules that selectively inhibit the growth of KRAS mutant cell lines in soft agar is reported, identifying the target of the most KRAS-selective chemical series as dihydroorotate dehydrogenase (DHODH).
99
Abstract 2243: Clonogenic 3D high throughput screening in mutant KRAS dependent cancer cells - a chemogenomic approach.
Malvika Koundinya,Judith Sudhalter,Albane Courjaud,Bruno Lionne,Gaetan Touyer,Luc Bonnet,Isabelle Menguy,Isabelle Schreiber,Christelle Perrault,Stephanie Vougier,Brigitte Benhamou,Daniel Simard,Maria Paola Castaldi,Ronald Tomlinson,Stephan Reiling,Hui Cao,David P. Harper,Monsif Bouaboula,Jack Pollard,Claudine Grepin,Carlos Garcia-Echeverria,Francisco Adrian,Ivan Cornella-Taracido,Rosalia Arrebola,Aaron J. Morris +24 more
TL;DR: A multi-cell line parallel phenotypic high throughput screen with a proprietary compound collection has led to the identification of several chemical classes that inhibit the growth of multiple mutant KRAS cell lines of pancreatic and colorectal carcinoma origin, while sparing multiple wild-type KRAS cancer cell lines.
1